Israel's largest drugmaker, Teva Pharmaceutical Industries, hasreported net income of $54.8 million for the first quarter of 2001, a rise of 56% compared with the like, year-earlier period, while earnings per share increased 43% to $0.40. Net sales for the quarter rose 46% to $491 million.
Growth was driven by North American sales (which made up 59% of total turnover), due mainly to the consolidation of Novopharm, but also as a result of new products launched since late 2000. Turnover in Europe made up 24% of sales, with Israel contributing 12%.
In terms of products, Teva's multiple sclerosis drug Copaxone (glatiramer acetate) was again the star performer, achieving sales of $74 million, an increase of 50%. The company noted that Copaxone now has a US market share of 29.8% of new prescriptions, compared with 23.9% a year ago.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze